**Market Brief: Strides Pharma Science Q3 FY26 Results** **Strides Pharma Science Ltd** has reported a robust financial performance for the third quarter ended **December 31, 2025**, driven by operational efficiency and significant one-time gains. The results triggered immediate bullish sentiment, with the stock witnessing a sharp rally in Friday's trade. **Financial Highlights** * **Net Profit:** Consolidated net profit surged over **2x** to **Rs 208.12 crore** year-on-year (YoY), compared to **Rs 90.04 crore** in the same quarter last fiscal. * **Revenue:** Consolidated revenue from operations grew moderately by **3.6%** to **Rs 1,194.65 crore**, up from **Rs 1,153.67 crore** in Q3 FY25. * **EBITDA:** The company achieved its highest-ever quarterly EBITDA of **Rs 235.9 crore**, reflecting a **12.2%** increase YoY. EBITDA margins expanded by **160 basis points** to **19.8%**, signaling improved operational health. **Key Growth Drivers** * **Operational Boost:** The growth was primarily fueled by strong performance in **"Other Regulated Markets"** and **"Growth Markets,"** which helped offset flat performance in the US business. * **Exceptional Income:** A significant contributor to the bottom line was a one-time gain of **Rs 102.14 crore** from the sale of an investment property (land and building), which boosted reported profits beyond operational growth. * **Margins:** Gross margins improved substantially to **61.2%** (up **280 bps** YoY), attributed to a better product mix and cost control measures. **Market Reaction** Following the announcement, Strides Pharma shares witnessed strong buying interest on Friday, January 30, 2026. The stock surged approximately **8-10%** intraday, closing near **Rs 876–886** levels, outperforming the broader market trend. Trading volumes spiked nearly **tenfold**, indicating high investor conviction. **Management Commentary** MD & Group CEO **Badree Komandur** emphasized that the results demonstrate consistent execution and a strategic pivot toward profitability. While the US market remained flat, the company is actively strengthening its leadership there with the recent appointment of a new CEO for the North America business to drive future growth. **Next Steps** Monitor the sustainment of EBITDA margins in the upcoming quarters and the impact of the new North America leadership on US revenue trajectories.